Cat. #151426
Anti-LAT1 [BU53]
Cat. #: 151426
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 1-2 weeks
Target: Large neutral Amino acid Transporter 1 (LAT1, CD98)
Class: Monoclonal
Application: FACS ; IHC
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Jefferis
Institute: University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-LAT1 [BU53]
- Alternate name: Solute Carrier Family 7 Member 5; L-Type Amino Acid Transporter; Integral Membrane Protein E16; CD98 Light Chain; 4F2 Light Chain; MPE16; HLAT1; LAT1; Sodium-Independent Neutral Amino Acid Transporter LAT1; Large Neutral Amino Acids Transporter 1; D16S469E; CD98LC; CD98; E16
- Research fields: Cancer;Cell signaling and signal transduction;Metabolism
- Clone: BU53
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC
- Description: Monoclonal antibody directed against LAT1 transporter channel protein and can aid investigation into amino acid transporter channel upregulation, a common mutation in oncogenesis.
- Immunogen: Plasma cell line 8226
- Immunogen uniprot id: Q01650
- Isotype: IgG1 kappa
Target Details
- Target: Large neutral Amino acid Transporter 1 (LAT1, CD98)
- Target background: LAT1, also known as SLC7A5, is part of the APC superfamily and forms a heterodimeric amino acid transporter channel. LAT1 interacts with CD98 glycoprotein via a conserved disulphide. This transporter channel is involved in the uptake of essential amino acids in various regions, particularly the placenta and blood brain barrier. LAT1 expressed on numerous cell types including B cells, activated T cells, monocytes, granulocytes, erythrocytes and endothelial cells. LAT1 is up-regulated on leucocytes in inflammatory lesions and is strongly expressed by neoplastic cells. Changes in amino acid transporter expression, including LAT1, are thought to be an early change in oncogenesis, as they provide growth and survival advantages.
Applications
- Application: FACS ; IHC
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
- Shipping conditions: Shipping at 4° C
References
- Cho et al. 2001. Blood. 98(2):374-82. PMID: 11435306.
- The Fn interactions between CD98, beta1-integrins, and CD147 in the induction of U937 homotypic aggregation.
- Leukocyte Typing VI 1997 Garland Publishing.
